Bionovo Appoints Dr. Klaus Kohl as Chief Technical Officer
EMERYVILLE, Calif., June 2 /PRNewswire-FirstCall/ -- Bionovo Inc. (Nasdaq:
BNVI) announced today the appointment of Klaus Kohl, Ph.D., as Senior Vice
President and Chief Technical Officer. Dr. Kohl brings to Bionovo over 20
years of experience in product development and manufacturing. Dr. Kohl will
be responsible for manufacturing, quality assurance, and regulatory
"We are very excited to add Dr. Kohl to our management team," said Isaac
Cohen, O.M.D., Bionovo's Chairman and CEO. He added, "We believe Dr. Kohl's
extensive background in the pharmaceutical industry will prove invaluable to
Bionovo's current efforts. Klaus' two decades of experience and broad
knowledge will optimize our organization to meet with partnering and
Dr. Kohl's most recent position was as Vice President of Program
Management, CMC and Regulatory Affairs at Novo Nordisk Delivery Technologies,
where he was responsible for the development of an inhaled insulin drug/device
combination product. Prior to Novo Nordisk, Dr. Kohl served as Senior Vice
President, Quality and Technical Director at Aradigm Corporation, a specialty
pharmaceutical development company focused on respiratory disease management.
From 1985 to 2001, Dr. Kohl worked for Bayer Corporation, where he held
various executive positions in quality assurance and drug product development.
Before Bayer, Dr. Kohl was engaged in basic research for more than seven years
at the Juelich Research Center in Germany, and the Max Planck Institute in
Dr. Kohl holds an undergraduate degree in Mathematics and Physics from the
University of Marburg, Germany, and a master's degree in Experimental Physics
and Ph.D. in Biophysics from the University of Aachen, Germany.
Dr. Kohl states, "I feel I am joining Bionovo at a very fitting moment,
when my experience, technical knowledge and regulatory understanding can
greatly contribute to the company's success. I believe Menerba is a
groundbreaking product that will provide a safer treatment for women suffering
from menopausal symptoms, and I look forward to contributing to its successful
Bionovo is a pharmaceutical company focused on the discovery and
development of safe and effective treatments for women's health and cancer,
markets with significant unmet needs and billions in potential annual revenue.
The company applies its expertise in the biology of menopause and cancer to
design new drugs derived from botanical sources which have novel mechanisms of
action. Based on the results of early and mid-stage clinical trials, Bionovo
believes they have discovered new classes of drug candidates within their rich
pipeline with the potential to be leaders in their markets. Bionovo is
headquartered in Emeryville, California and is traded on the NASDAQ Capital
Market under the symbol, "BNVI". For more information about Bionovo and its
programs, visit: http://www.bionovo.com.
Forward Looking Statements
This release contains certain forward-looking statements relating to the
business of Bionovo, Inc. that can be identified by the use of forward-looking
terminology such as "believes," "expects," or similar expressions. Such
forward-looking statements involve known and unknown risks and uncertainties,
including uncertainties relating to product development, efficacy and safety,
regulatory actions or delays, the ability to obtain or maintain patent or
other proprietary intellectual property protection, market acceptance,
physician acceptance, third party reimbursement, future capital requirements,
competition in general and other factors that may cause actual results to be
materially different from those described herein as anticipated, believed,
estimated or expected. Certain of these risks and uncertainties are or will be
described in greater detail in our filings with the Securities and Exchange
Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under
no obligation (and expressly disclaims any such obligation) to update or alter
its forward-looking statements whether as a result of new information, future
events or otherwise.
SOURCE Bionovo, Inc.
/CONTACT: Claire Fong or Tom Chesterman both of Bionovo Inc.,
/Web Site: http://www.bionovo.com /
CO: Bionovo, Inc.
IN: MTC BIO HEA